Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 60 months or greater · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful treatment of exacerbation: number of participants cured. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants cured.… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Successful treatment of exacerbation: number of participants with P aeruginosa eradication. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants with P… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Relapse · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Microbiological response: eradicated. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Hospital admissions · bronchiectasis
1 finding from 1 review
Death · bronchiectasis
1 finding from 1 review
Quality of life · bronchiectasis
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with oral omega‐6 PUFAs (moderate certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in ocular surface staining at 1‐month compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs may leads to higher adverse event: gastrointestinal disorders at 1‐month (with actual compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review